• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EQUIMATRIX CANCELLOUS (8503-06-0025); NATURAL BONE MINERAL MATRIX

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EQUIMATRIX CANCELLOUS (8503-06-0025); NATURAL BONE MINERAL MATRIX Back to Search Results
Device Problems Improper or Incorrect Procedure or Method (2017); Device Operates Differently Than Expected (2913)
Patient Problems Inflammation (1932); Pain (1994); Patient Problem/Medical Problem (2688)
Event Type  Injury  
Event Description
On (b)(6) 2015, an initial, spontaneous report was received by(b)(4) from a dentist via an email from a sales representative concerning the second of three patients (patient identifiers not provided) who was administered equimatrix cancellous (no product information provided) and the bone dissolved 1 week after grafting with equimatrix (meddra: graft loss).No further information was provided.On (b)(6) 2015, additional information was received from the dentist via telephone contact from a company representative.This case report was referenced by the dentist as case #2 (the second of 8 patients) which involved tooth #5, the maxillary right first premolar that was removed.An osteotome sinus lift was performed an immediate implant placed and the gap between the alveolus and implant body was grafted with equimatrix.At one week, the patient experienced significant pain (meddra: pain).At 2.5 months post-surgery, a periapical radiograph was taken, revealing a huge (per the reporter), radiolucent lesion that appeared to be palatally positioned (meddra:palatal defect).The implant was removed (meddra: device failure) exposing large amounts of inflammatory/granulomatous tissue (meddra: soft tissue inflammation and excessive granulation tissue, respectively), all of which was debrided from the area.No sign of purulent drainage was evident.The palatal and buccal plates of bone were resorbed (meddra: bone loss).The dentist considers the equimatrix related to the events.Upon medical review, the following events were considered serious, required intervention: significant pain, radiolucent lesion palatally positioned, palatal and buccal bones resorbed and implant removed.No further information provided.Company assessment: increased implant and graft failure rates can be expected in patients exhibiting risk factors such as systemic diseases, smokers, chronic periodontitis, and periapical pathology.In addition, certain anatomic factors including thin tissue biotype, buccal wall defects, and poor bone density are important determinants of risk assessment.The following comments apply to all equimatrix cases reported by the dentist.The causality assessment of all cases is hampered due to a lack of detailed information: no patient identifiers were furnished no patient demographic information, social history, or habit history was provided no information regarding patients' medical history, past dental history, medications or current medical status that might influence normal wound healing was provided no clinical or radiographic diagnosis (except as noted in individual reports) no description of details of treatment rendered no specification of concomitant medical devices used during surgery (except as noted) such as other graft materials, implant type, membranes, etc.No details of the surgical procedures were provided and there was no information about how graft materials were protected during healing no comments on occlusal analysis or occlusal status and parafunctional habits was provided radiographs were not provided for the majority of cases.When provided, they were not labeled or dated (except as noted).Cbct images provided were screen shots that were not labeled and in some cases not dated.Pre- and post-surgery cbct images were from different sections and could not be compared.Radiographic and cbct images did not coincide with description provided by the dentist in the accompanying e-mails.Tooth number and implant sites were not specified for cases and sites with complications were not always identified.Based on company representative's telephone conversation with the dentist on (b)(6) 2015, no flaps were reflected prior to initiating any surgery potentially limiting a thorough direct clinical examination following tooth removal as well as possibly compromising a thorough postextraction debridement of each treated site.According to the package insert, "in order to assure the formation of new bone, equimatrix should only be placed in direct contact with well vascularized bone.Cortical bone should be mechanically perforated, if necessary." without reflecting a flap, it would be impossible to determine whether the equimatrix was being placed in direct contact with well-vascularized bone, especially if significant socket wall defects were present without reflecting a flap, it would be difficult, at best, to: determine whether the inner socket walls require mechanical perforations as well as making such perforations exceedingly difficult to carry out.If cortical perforation in order to increase the blood supply to the grafted areas were needed and possible, such perforation would need to be accomplished prior to implant placement.There is no indication that any cortical perforation was carried out prior to implant placement for any of the cases discussed by the dentist.According to the package insert, "after exposure of the bony defect with a full thickness mucoperiosteal flap, all granulation tissue must be carefully removed." therefore, according to the equimatrix package insert, and supported by numerous clinical photos found in the equimatrix brochure, a full-thickness flap is required prior to equimatrix graft particle placement.According to the dentist, all cases grafted with equimatrix were performed "flapless".According to the package insert and included in the equimatrix.Brochure sent to clinicians, "sites grafted with equimatrix should be allowed to heal approximately 6 months prior to implant placement." in other words, immediate implant placement following tooth removal is not an approved indication when using equimatrix.Of the three cases discussed in some detail, all were immediately placed implants grafted with equimatrix.There is no information about the pre-extraction diagnosis for each area treated.Why the teeth required removal in the first place could impact on the final post-implant and grafting results both in the short and long-term.It appears that all implants in the reported cases received immediate temporary restorations.It is not known if premature loading of the implants was a factor in the graft and implant failure.In this case, the dentist performed a series of technique sensitive procedures using a flapless approach.There are many aspects of the extraction, osteotome sinus lift, immediate implant placement, and temporization that could have contributed to the graft and implant failure.In summary, based on the available facts, the improper performance of the clinician is the primary cause for the poor outcome.The extensive bone loss that occurred was due to the failure of the dentist to address the post-operative complications in a timely manner when the patient was having protracted pain and not due to the equimatrix.Manufacturer product assessment: (b)(4) in collaboration with nibec, the manufacturer of equimatrix has conducted an investigation into the equimatrix customer complaints.This investigation included a review of the manufacturing process for the following product batches: uh134011s, uh134292b, uh134322b, uh134332b, uh134392b, and uh134421b.This review included an in-depth review of the batch records and a critical analysis including sterility test, protein assay and endotoxin test, which may be related to the effectiveness of the products.The batch record review indicated that all manufacturing procedures complied with the manufacturing sop with no deviation.The critical biologic analysis performed on the following batches: uh134011s, uh134292b, uh134322b, uh134332b, uh134392b, and uh134421b demonstrated that the product is maintained sterile, the protein content is well below the critical limit, and endotoxin was not detected.Based on the investigation conducted, it can be concluded that no abnormalities could be identified in the manufacturing process and this product has been demonstrated to conform to the current approved specification.A complete company causality assessment and manufacturer product quality assessment have been attached for further review.Upon internal review, it was determined to submit this case as a non-expedited report.This case is linked to (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EQUIMATRIX CANCELLOUS (8503-06-0025)
Type of Device
NATURAL BONE MINERAL MATRIX
MDR Report Key5308203
MDR Text Key33860209
Report Number2410375-2015-00002
Device Sequence Number1
Product Code DZE
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Distributor
Reporter Occupation Other
Type of Report Initial
Report Date 12/15/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received12/17/2015
Type of Device Usage N
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-